Epoxyeicosatrienoic acids - Novel mechanism and pharmacological therapy of chronic renocardiac syndrome

Medical Hypotheses

Volumn 76, Issue 4, 2011, Pages 550-552

  Huang, Hui ^a   Chen, Jie ^a   Lin, Tianxin ^a   Wang, Tong ^a   Tang, Yi ^c   Dong, Yanbing ^b   Wang, Jingfeng ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; CYTOCHROME P450; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; LAURIC ACID; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC RENOCARDIAC SYNDROME; DISEASE COURSE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART DISEASE; HEART VENTRICLE HYPERTROPHY; HEPATORENAL SYNDROME; HYPERTENSION; KIDNEY DYSFUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION;

8,11,14-EICOSATRIENOIC ACID; CHRONIC DISEASE; HEART DISEASES; HUMANS; KIDNEY DISEASES; SYNDROME;

EID: 79952315682     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.12.015     Document Type: Article

References (20)

1. Smith G.L., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47(10):1987-1996.
2. Ronco C., et al. Cardiorenal syndrome. J Am Coll Cardiol 2008, 52(19):1527-1539.
3. Bagshaw S.M., Cruz D.N. Epidemiology of cardiorenal syndromes. Contrib Nephrol 2010, 165:68-82.
4. Sarraf M., Masoumi A., Schrier R.W. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009, 4(12):2013-2026.
5. Medhora M., et al. Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat 2007, 82(1-4):19-29.
6. Farese S. Cross-talk between heart and kidney - mechanisms and management of the cardiorenal syndrome from a nephrologists view. Ther Umsch 2009, 66(11):741-746.
7. Mahapatra H.S., et al. Cardiorenal syndrome. Iran J Kidney Dis 2009, 3(2):61-70.
8. Tsao C.C., et al. Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio- and stereoselective products. J Pharmacol Exp Ther 2001, 299(1):39-47.
9. Zordoky B.N., Aboutabl M.E., El-Kadi A.O. Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab Dispos 2008, 36(11):2277-2286.
10. Anwar-mohamed A., et al. Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 2010, 61(5):410-418.
11. Jung O., et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45(4):759-765.
12. Hercule H.C., et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009, 29(1):54-60.
13. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res 2001, 89(9):753-762.
14. Miyazono M., et al. Increased epoxyeicosatrienoic acid formation in the rat kidney during liver cirrhosis. J Am Soc Nephrol 2003, 14(7):1766-1775.
15. Qiu H et al. Soluble epoxide hydrolase inhibitors and heart failure. Cardiovasc Ther. 2010, April 23 [Epub ahead of print] PMID:20433684.
16. Jung O., et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One 2010, 5(8):e11979.
17. Lee C.R., et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010, 24(10):3770-3781.
18. Minuz P., et al. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 2008, 51(5):1379-1385.
19. Luria A., et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 2007, 282(5):2891-2898.
20. Hutchens M.P., et al. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation 2008, 76(1):89-94.